Amarin Valuation

Is AMRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AMRN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AMRN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMRN?

Key metric: As AMRN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AMRN. This is calculated by dividing AMRN's market cap by their current revenue.
What is AMRN's PS Ratio?
PS Ratio	0.8x
Sales	US$241.02m
Market Cap	US$201.84m

AMRN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AMRN's PS Ratio compare to its peers?

The above table shows the PS ratio for AMRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	22.3x
FATE Fate Therapeutics	18.8x	8.8%	US$248.3m
ENTA Enanta Pharmaceuticals	2.7x	12.8%	US$199.6m
ELUT Elutia	6x	45.5%	US$143.4m
PGEN Precigen	61.8x	62.5%	US$233.0m
AMRN Amarin	0.8x	-3.2%	US$201.8m

Price-To-Sales vs Peers: AMRN is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (22.3x).

Price to Sales Ratio vs Industry

How does AMRN's PS Ratio compare vs other companies in the US Biotechs Industry?

131 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	10.1x	21.6%
AMRN Amarin	0.8x	-3.2%	US$201.84m
GILD Gilead Sciences	3.9x	2.4%	US$109.25b
BIIB Biogen	2.4x	1.3%	US$22.65b

131 Companies		Estimated Growth	Market Cap
Industry Avg.	10.1x	28.3%
AMRN Amarin	0.8x	-7.7%	US$201.84m

No more companies

Price-To-Sales vs Industry: AMRN is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is AMRN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMRN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	1.4x

Price-To-Sales vs Fair Ratio: AMRN is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

-0.6%

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

-7.9%

6.6%

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

-8.1%

-7.2%